The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10033 malaria professionals are enjoying the free benefits of MalariaWorld today

Scientific Articles

Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS, S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys

December 5, 2009 - 16:19 -- Kabogo Ndegwa
Author(s): 
S. Pichyangkul, P. Tongtawe, U. Kum-Arb, K. Yongvanitchit, M. Gettayacamin, M.R. Hollingdale, A. Limsalakpetch, V.A. Stewart, D.E. Lanar, S. Dutta, E. Angov, L.A Ware, E.S. Bergmann-Leitner, B. House, G. Voss, M.C. Dubois, J.D. Cohen, M.M. Fukuda, D.G. Heppner, R.S. Miller.
Reference: 
Vaccine, Volume 28, Issue 2, 11 December 2009, Pages 452-462, doi:10.1016/j.vaccine.2009.10.022

In an effort to broaden the immune response induced by the RTS,S/AS02A,vaccine, we have evaluated the immunogenicity of the RTS,S antigen when combined with MSP142 and with AMA1, antigens derived from the asexual blood stage.

Technology: 
Medical Condition: 

Effectiveness of malaria chemoprophylaxis against Plasmodium falciparum infection in UK travellers: Retrospective observational data

December 4, 2009 - 16:07 -- Patrick Sampao
Author(s): 
Jane N. Zuckerman, Anthony J. Batty, Michael E. Jones.
Reference: 
Travel Medicine and Infectious Disease, Volume 7, Issue 6, November 2009, Pages 329-336, doi:10.1016/j.tmaid.2009.10.002.

Further work is required to ascertain whether ease of use and compliance may be important factors in the outcomes associated with malariachemoprophylaxis.

Person: 
Country: 
Medical Condition: 
Medical Treatment: 

Anopheles mosquito transmission of brain tumor

December 4, 2009 - 16:00 -- Patrick Sampao
Author(s): 
Steven Lehrer
Reference: 
Medical Hypotheses, Volume 74, Issue 1, January 2010, Pages 167-168, doi:10.1016/j.mehy.2009.07.005 R

If a mosquito-transmitted brain tumor virus could be identified, development of a brain tumor vaccine might be possible.

Medical Condition: 

Comparing human T cell and NK cell responses in viral-based malaria vaccine trials

December 3, 2009 - 12:17 -- Patrick Sampao
Tags: 
Author(s): 
Tamara K. Berthoud, Helen Fletcher, David Porter, Fiona Thompson, Adrian V.S. Hill, Stephen M. Todryk
Reference: 
Vaccine, Volume 28, Issue 1, 10 December 2009, Pages 21-27

In conclusion, measuring antigen-specific T cells is more meaningful than NK cells in these vaccination regimens.

Medical Treatment: 

Household risk factors for clinical malaria in a semi-urban area of Burkina Faso: a case–control study

December 3, 2009 - 12:13 -- Patrick Sampao
Author(s): 
S. Yamamotoa, V.R. Louisa, A. Siéb and R. Sauerborna
Reference: 
Transactions of the Royal Society of Tropical Medicine and Hygiene, Volume 104, Issue 1, January 2010, Pages 61-65, doi:10.1016/j.trstmh.2009.07.003.

This study examined the effect of different housing and household characteristics on malaria risk among 98 case and 185 control children in the semi-urban area of Nouna, Burkina Faso.

Technology: 
Country: 
Medical Condition: 

Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection.

December 3, 2009 - 12:11 -- Kabogo Ndegwa
Author(s): 
Manuel A. Giraldo, Gabriela Arevalo-Pinzon, Jose Rojas-Caraballo, Alvaro Mongui, Raul Rodriguez, Manuel A. Patarroyo
Reference: 
Vaccine, Volume 28, Issue 1, 10 December 2009, Pages 7-13, doi:10.1016/j.vaccine.2009.09.046.

In this study, the P. vivax merozoite surface protein 10 (MSP-10) was expressed as a recombinant protein in Escherichia coli and purified by affinity chromatography. 

Medical Treatment: 

Immunogenicity and antigenic properties of Pf332-C231, a fragment of a non-repeat region of the Plasmodium falciparum antigen Pf332.

December 3, 2009 - 12:08 -- Kabogo Ndegwa
Author(s): 
H.A. Balogun, N.-M. Vasconcelos, R. Lindberg, M. Haeggström, K. Moll, Q. Chen, M. Wahlgren, K. Berzins
Reference: 
Vaccine, Volume 28, Issue 1, 10 December 2009, Pages 90-97, doi:10.1016/j.vaccine.2009.09.110

Antigen Pf332, a megadalton protein has been shown to be associated with the membrane of infected erythrocytes. Detailed functional studies on the antigen have remained hampered by the cross-reactive nature of antibodies generated to Pf332. Pf332-C231, identified in the C-terminal region of Pf332 was cloned and antibodies against the C231 fragment were shown to react with intact Pf332 antigen by both immunofluorescence and immunoblotting analyses. Antibodies to C231 inhibited in vitro Plasmodium falciparum growth efficiently.

Argemone Mexicana decoction versus artesunate-amodiaquine for the management of malaria in Mali: policy and public-health implications.

December 3, 2009 - 12:07 -- Patrick Sampao
Author(s): 
Bertrand Graz, Merlin L. Willcox, Chiaka Diakite, Jacques Falquet, Florent Dackuo, Oumar Sidibe, Sergio Giani, Drissa Diallo
Reference: 
Transactions of the Royal Society of Tropical Medicine and Hygiene, Volume 104, Issue 1, January 2010, Pages 33-41, doi:10.1016/j.trstmh.2009.07.005

A classic way of delaying drug resistance is to use an alternative when possible. We tested the malaria treatment Argemone mexicana decoction (AM), a validated self-prepared traditional medicine made with one widely available plant and safe across wide dose variations. In an attempt to reflect the real situation in the home-based management of malaria in a remote Malian village, 301 patients with presumed uncomplicated malaria (median age 5 years) were randomly assigned to receive AM or artesunate-amodiaquine [artemisinin combination therapy (ACT)] as first-line treatment.

Country: 
Medical Condition: 

Priorities in research and development of vaccines against Plasmodium vivax malaria

December 3, 2009 - 12:05 -- Kabogo Ndegwa
Tags: 
Author(s): 
Graham V. Brown, Vasee S. Moorthy, Zarifah Reed, Kamini Mendis, Myriam Arévalo-Herrera, Pedro Alonso.
Reference: 
Vaccine, Volume 27, Issue 52, 9 December 2009, Pages 7228-7235, doi:10.1016/j.vaccine.2009.08.112

The WHO Initiative for Vaccine Research (IVR) Malaria Vaccine Advisory Committee (MALVAC) provides advice to WHO on priorities in malaria vaccine research and development (R&D). 

Medical Condition: 
Medical Treatment: 

Open Access | Interaction of Artemisinins with Oxyhemoglobin Hb-FeII, Hb-FeII, CarboxyHb-FeII, Heme-FeII, and Carboxyheme FeII: Significance for Mode of Action and Implications for Therapy of Cerebral Malaria

December 3, 2009 - 12:01 -- Patrick Sampao
Author(s): 
Paolo Coghi, Nicoletta Basilico, Donatella Taramelli, Wing-Chi Chan, Richard K. Haynes, Diego Monti
Reference: 
ChemMedChem Volume 4, Issue 12, Date: December 7, 2009, Pages: 2045-2053

The findings not only indicate that artemisinins do not require Hb-FeII or heme-FeII for promotion of antimalarial activity, but are also important in relation to the therapy of severe/complicated or cerebral malaria.

Medical Condition: 
Medical Treatment: 

Pages

Subscribe to Scientific Articles